FDA Generic “Shared” Exclusivity Policy Needs Judicial Clarity, Troy Says
Executive Summary
FDA's patent-based approach to awarding generic marketing exclusivity is the only remaining issue of legal uncertainty under the original Waxman/Hatch framework, former FDA Chief Counsel Dan Troy said
You may also be interested in...
“Authorized” Generic Opponents Turn To State Laws After Federal Court Loss
Generic companies are pursuing alternative litigation routes in their efforts to block "authorized" generics following a Washington, D.C. appeals court decision upholding FDA's current policy on the products
“Authorized” Generic Opponents Turn To State Laws After Federal Court Loss
Generic companies are pursuing alternative litigation routes in their efforts to block "authorized" generics following a Washington, D.C. appeals court decision upholding FDA's current policy on the products
Apotex Sues FDA Over Gabapentin ANDAs, Says Purepac Exclusivity Has Run
Apotex is suing FDA for immediate approval of its ANDA for a generic version of Pfizer's Neurontin